Introduction
The therapeutic efficacy of stem cells largely relies on their ability to replicate. Therefore, strategies to manipulate stem cells require an understanding of their cell cycle control. In this review, the distinct cell cycle kinetics of adult stem cells will be introduced and briefly followed by the current understanding of general cell cycle regulation in mammalian cells. The focus will be placed on the specific impact of the cell cycle inhibitors, namely the roles of cyclin-dependent kinase inhibitors (CKIs) on adult stem/progenitor cells. While many stem cell types have been or are being defined, the hematopoietic stem cell (HSC) remains one of the best-studied stem cell types and therefore data have been largely obtained from HSCs partially in comparison with the other stem cell types such as the neural stem cell (NSC). The distinct impacts of different CKIs in stem cell populations underscore the crucial role that cell cycle inhibitors play in stem cell regulation and offer new insights into the mechanisms of cancer development, especially in light of the concept of 'tumor stem cell' (TSC) (or described as 'cancer stem cell' in general or 'leukemic stem cells' in leukemias by some other investigators in the field). The biochemical pathways of general cell cycle regulation will not be detailed in the current review, since they have been extensively reviewed elsewhere (Pardee, 1989; Sherr and Roberts, 1999; Sherr, 2000) .
Stem cell proliferation with a limited rate
By definition, stem cells have the ability to reproduce themselves indefinitely while possessing the potential to differentiate into multiple lineages (or a single lineage in a few tissue types) via transit amplifying cells (progenitors) . However, the proliferative rate of stem cells in vivo under physiological conditions is much slower compared to that of intermediate progenies, including the progenitor cells and proliferating precursors.
In the hematopoietic system, an increase in stem cell divisions can take place (Pawliuk et al., 1996; Oostendorp et al., 2000) under activating conditions, such as after transplantation or the depletion of cycling cells using the S-phase toxin (5-fluorouracil or hydroxyurea) (Harrison and Lerner, 1991; Uchida et al., 1997) . However, the relative quiescence of the HSC pool appears to be essential to prevent premature depletion under conditions of physiologic stress over the lifetime of the organism (Cheng et al., 2000a, b) . The highly regulated proliferation of HSC occurs at a very limited rate under homeostatic conditions. It had once been hypothesized that the stem cell quiescence reflects a complete cell cycle arrest of the majority cells in the stem cell compartment, termed the 'clonal succession model' (Kay, 1965) . While the retrovirus-based clonal marking studies revealed few active stem cell clones at a given time, which supports the clonal succession theory (Lemischka et al., 1986) , this view has been challenged by the competitive repopulation model (Harrison et al., 1988) or 5-bromodeoxyuridine (BrdU) incorporation in the defined stem cell pools with a simulation methodology (Cheshier et al., 1999) . Using BrdU labeling experiments, cell cycle lengths were estimated at approximately 30 days in small rodents (Bradford et al., 1997) and it was found that only about 8% of the cells are in cell cycle daily (Cheshier et al., 1999) . Similar analyses using population kinetics estimated that stem cells replicate once per 10 weeks in cats (Abkowitz et al., 1996) . In non-human primates, the rate of cell replication in the stem cell pool was estimated to be once per year (Mahmud et al., 2001) . In contrast, the essential feature of the hematopoietic progenitor cell (HPC) population is that it irreversibly develops into maturing cells, and in the process undergoes multiple rapid cell divisions. The progenitor cell pool essentially operates as a cellular amplification machine, generating many differentiated cells from the few cells entering the system (Potten, 1997) , and it is therefore directly responsible for the number of terminally differentiated cells. For this reason, the progenitor cell pool is also termed the transit, amplifying cell pool. The differences between the stem and progenitor cell populations have been regarded as phenotypic distinctions marking the stage of a cell within the hematopoietic cascade. However, an alternative model was recently put forward proposing that the specific position in a cell cycle determines whether a primitive cell functions as a stem or a progenitor cell (Quesenberry et al., 2002) . In this hypothetical model, stimuli received at distinct positions in the cell cycle provoke proliferation/differentiation or not, and thereby yield either HSC or HPC outcomes. This seems to contradict the traditional view of 'hierarchy' within the hematopoietic differentiation. Nevertheless, in either model, 'stemness' is associated with the limited rate of the cell proliferation.
The slow cycling feature seems to be a common feature in most adult stem cell types if not all (Potten, 1997) . In the central nervous system (CNS), evidence suggests that the proliferative pools of adult neural progenitors are derived from a quiescent multipotent neural precursor or NSC (Bonfanti et al., 2001; Palmer et al., 2001) . For example, if the proliferative zone containing the lineage-committed neuronal progenitor cells (NPC) is ablated, it can be repopulated from a small number of quiescent NSCs (Morshead et al., 1994; Doetsch et al., 1999) . Perhaps largely owing to this quiescence, endogenous NSCs do not produce complete recovery in cases of severe injury, though they do participate in self-repair after brain damage (Horner et al., 2000) . In the mouse dermal stem cell population, there are about fourfold fewer cells in S-G2/M phases in the stem cell population compared with the progenitor pool, though both cell populations constantly proceed through the cell cycle (Dunnwald et al., 2003) . In addition, epithelial stem cells in mouse cornea (Cotsarelis et al., 1989) or mouse hair follicle (Morris et al., 2004) appear to be slowly cycling as well.
The relative quiescence of stem cells may prevent their premature exhaustion in vivo, but it has been considered to be one of the hurdles in the context of the in vitro expansion necessary for stem cell transplantation and gene therapy. Methods for inducing stem cell proliferation have long been sought as a means to expand the population of cells capable of repopulating the bone marrow of ablated hosts and to render stem cells transducable with virus-based gene transfer vectors. Although great effort has been made to directly expand stem cells using different combinations of hematopoietic growth factors (cytokine cocktails), no culture system has been applied successfully in clinical settings. This is due, in part, to the lack of proof that any of the culture conditions support expansion of a long-term repopulating HSC in humans (Verfaillie, 2002) . Although data suggest that under certain specific conditions murine HSCs may divide in vitro, net expansion is achieved in limited fashion and is associated with and often dominated by cellular differentiation (Ema et al., 2000; Uchida et al., 2003) . It remains unclear which combination of hematopoietic cytokines is specifically selective for stem cell proliferation without differentiation. So far, there is no cytokine combination that can achieve the effect of stem cell expansion by the HoxB4 protein (Antonchuk et al., 2002) . A recent promising study demonstrated a potent effect of purified Wnt3a protein in the expansion of mouse HSC in vitro. But the effect appeared to require a strong survival element since the net expansion could be only achieved on the HSCs from the Bcl2 transgenic mice .
In short, the dichotomy of the relative resistance to proliferative signals by stem cells and the brisk responsiveness by progenitor cells is generally believed to be a central feature of tissue maintenance, although the phenotypic distinctions between stem and progenitor cells in many nonhematopoietic organs have not been fully defined. Nevertheless, the functional difference in proliferative response between stem cells and progenitors represents a challenge for the specific manipulations of the stem cells for therapeutic purposes. While a complex array of extracellular signals and intracellular transduction pathways certainly participate in the distinct response, the cell cycle machinery, as a final step, must communicate with the specific regulatory cues (Steinman and Nussenzweig, 2002) and cell cycle regulators must play key roles in this process (D'Urso G and S, 2001 ).
Cell cycle regulation and CDK inhibitors
The molecular principles of cell cycle regulation have been defined largely in yeast and in orthologous systems applicable to the mammalian cell cycle (Hartwell and Weinert, 1989) . A number of surveillance checkpoints monitor the cell cycle and halt its progression, mainly via the p53 pathway , when DNA damage occurs. In mammalian cells, the cell cycle machinery that determines whether cells will continue proliferating or will cease dividing and differentiate appear to operate mainly in the G1 phase (Figure 1 ). Cell cycle progression is regulated by the sequential activation and inactivation of CDKs (Sherr, 1994; Sherr and Roberts, 1995) . In somatic cells, movement through G1 and into the S phase is driven by the active form of the Cyclin D1, 2,3/CDK4, 6 complex and the subsequent phosphorylation retinoblastoma (Rb) protein (Classon and Harlow, 2002) . Once Rb is phosphorylated, the critical transcription factor, E2F-1, is partially released from an inhibited state and it turns on a series of genes including cyclin A and cyclin E that form a complex with CDK2 as well as cdc25A phosphatase. Cdc25A is able to remove the inhibitory phosphates from CDK2 and the resultant cyclin E/CDK2 complex, then it further phosphorylates Rb, leading to a complete release of E2F and the transcription of a series of genes essential for S-phase progression and DNA synthesis. In parallel, the c-Myc pathway also directly contributes to the G1/S transition by elevating the transcription for cyclin E and cdc25A (Bartek and Lukas, 2001) (Figure 1 ).
CDK activity is strictly dependent on cyclin levels that are regulated by proteosome-mediated proteolysis. Upon mitogenic stimulation, cyclin D serves as an essential sensor in the cell cycle machinery and interacts with the CDK4/6-Rb-E2F pathway. In addition to regulation by cyclins and phosphorylation/dephosphorylation of the catalytic subunit, CDKs are largely controlled by CKIs ARF in mice), through an alternative reading frame (ARF) (Sherr, 2001) . Intriguingly, ARF protein is able to activate p53 function by removing the inhibitory effect of Mdm2 on p53 protein (Sherr and Weber, 2000) . Therefore, the unique p16 locus serves as a bridging point between the two most frequently targeted networks in the cells of the majority of cancers: RB and p53 pathways. Both CKI families have been shown to be essential in arresting cell cycle progression in a broad spectrum of cell types (Morgan, 1995; Sherr, 1996) . Studies using antisense of p21 or p27 have been able to release the cells from Go stage into the cell cycle (Nakanishi et al., 1995; Rivard et al., 1996) . p27 and p18 have been proposed as intrinsic timers regulating animal organ size in an autonomous manner (Conlon and Raff, 1999) . While we have a wealth of knowledge about the biochemical roles of CKIs in a variety of model systems (Sherr, 1996; Sherr and Roberts, 1999; Sherr, 2000) , few experiments have been performed in the defined stem cell populations. There appears to be a distinct cell cycle control operating in stem cells in order to maintain their 'stemness'. Mouse embryonic stem (ES) cells were shown to have a 'defective' Rb pathway and a nonresponsive p53 pathway (Aladjem et al., 1998; Prost et al., 1998; Burdon et al., 2002) . In adult tissues, stem cells and progenitor cells share many common cytokine receptors (Berardi et al., 1995; Becker et al., 1999; Roy and Verfaillie, 1999; Shen et al., 1999) , it is likely that the distinct cell cycle profile in stem cells is mediated by either distinct upstream intracellular mediators or unique combinatorial relationships of common biochemical mediators that limit the intensity of signals to enter into cell cycle. Defining the mechanisms in the stem cell response requires the analysis of individual cell cycle regulators and ultimately a systematic approach to define how these cell cycle regulators interact with one another and intersect various signaling pathways.
Roles of CKIs in stem cell regulation
Roles of CKIs in stem and progenitor cells have been shown in several species since Dipio, an analogue of p21/ p27, was reported to control embryonic progenitor proliferation in Drosophila (de Nooij and Hariharan, 1995; de Nooij et al., 1996) . However, further study of their roles in stem cells from other higher species by conventional experiments in molecular biology is hampered due to the extremely limited availability of the primary stem cells. Fortunately, genetically engineered animal models and cell-sorting technologies allow us to vigorously test the gain or loss of gene function in the defined HSC and HPC populations in the hematopoietic system. CKI knockout rodent models have been particularly useful in providing a feasible approach for studying the roles of cell cycle inhibitors in stem cell biology (Brugarolas et al., 1995; Nakayama et al., 1996; Franklin et al., 1998) . In the hematopoietic system, most CKI family members have been found to be differentially expressed in human CD34 Cell cycle inhibitors in stem cells T Cheng (Taniguchi et al., 1999; Tschan et al., 1999; Yaroslavskiy et al., 1999; Marone et al., 2000; Cheng et al., 2001) , indicating their distinct effects in hematopoiesis. In the following paragraphs, the HSC will be most used as an example to describe the roles of CKIs in stem cell regulation unless other adult stem cell types are specified.
p21: a gatekeeper for quiescent stem cells p21 mRNA is abundant in quiescent human HSCs, while it is reduced in progenitor populations (Ducos et al., 2000; Stier et al., 2003) . Functional assessment in hematopoietic cells been carried out using p21À/À mice (Cheng et al., 2000a, b) . In the absence of p21, HSC proliferation tends to increase under normal homeostatic conditions. Exposing the animals to cell cyclespecific myelotoxic injury resulted in a higher rate of mortality due to hematopoietic cell depletion. Therefore, p21 governs cell cycle entry of stem cells, and its absence leads to increased proliferation of the primitive cells. However, self-renewal of HSCs was impaired in serially transplanted bone marrow from p21À/À mice (Cheng et al., 2000b) , suggesting that restricted cell cycling is crucial to prevent premature stem cell depletion and hematopoietic death under conditions of stress. Such results might not be solely attributed to the stem cell effect and other possible defects in differentiation or apoptosis program, especially in the downstream of the hematopoiesis, cannot be completely ruled out based on the study. Nevertheless, the increased HSC cycling that results from p21 absence in mice has recently been extended to human cells and to a nondevelopmental context. Using postnatal CD34 þ CD38 À human cells, it was shown that interrupting p21 expression with lentivectors ex vivo resulted in expanded stem cell number validated with the transplantation assay in irradiated NOD/SCID mice (Stier et al., 2003) . This study demonstrated a proof-of-concept for an alternative paradigm in which HSC numbers can be increased by releasing the brake on cell cycle entry rather than focusing on combinations of pro-proliferative cytokines that can also induce differentation. These data further supported the notion that postnatal human stem cell proliferation can be uncoupled from differentiation in ex vivo settings.
Given that relative quiescence is a common feature of different tissue stem cell types and that p21 maintains HSC quiescence, it was hypothesized that p21 might also participate in limiting NSC reactivity in vivo. Neural precursor cells from adults have exceptional proliferative and differentiative capabilities in vitro, yet respond minimally to in vivo brain injury due to constraining mechanisms that are poorly defined. The role of p21 in the regenerative response of neural tissue is evaluated in mice deficient in p21 following ischemic injury (Qiu et al., 2004) . While steady-state conditions revealed no increase in primitive cell proliferation in p21-null brain, which is different from that found in the hematopoietic system, a significantly larger fraction of quiescent neural precursors was activated in the hippocampus and subventricular zone after brain ischemia. The hippocampal precursors migrated and differentiated into a higher number of neurons post injury. In an earlier study, p21 null also promoted the skin stem cell potential in mice (Missero et al., 1996) . Therefore, p21 may serve as a common molecular regulator restricting proliferation among stem cell pools from distinct tissue types, despite the distinct kinetics between different tissue types.
Paradoxically, the role of p21 has been noted to positively affect proliferation following cytokine stimulation in progenitor cell pools (Liu et al., 1996) . This may be due to the requirement for p21 to promote the association of CDK4 with D-type cyclins. LaBaer et al. (1997) demonstrated that low concentrations of p21 promote assembly of active kinase complexes and thereby entry into cycle, whereas higher concentrations are inhibitory. The stoichiometry of p21 and cyclin-CDK complexes appears to be crucial in determining the relative effect on movement of the cell through late the G1 into S phase. This was further confirmed in a study showing that p21 and p27 are essential activators of cyclin D-dependent kinases in murine fibroblasts . Mantel et al. (1996) noted that bone marrow progenitor cells from p21-null mice proliferated poorly and formed fewer colonies with thymidine treatment except when transduced with a p21-encoding retroviral vector (Braun et al., 1998) . Similarly, these defects were complemented by a transient rise in p21 immediately following release of cell cycle arrest in the murine myeloid progenitor 32D cell line . Therefore, as observed in other systems, p21 has a dual function in the hematopoietic system, depending on the differentiation stage and CDK complex type and status. In addition, complex roles of p21 in apoptosis (Wang and Walsh, 1996) or differentiation (Steinman et al., 1994 (Steinman et al., , 1998 may also participate in stem cell regulation, though these functions are yet to be thoroughly investigated. With regard to cell cycle regulation, it is unclear why the positive role of p21 in forming the complex of CDK4 or CDK6 with D-type cyclins dominates its inhibitory effect on CDK2 activity in the progenitor cell pools.
It is also unclear why p21 expression is elevated in quiescent HSCs. Two direct upstream regulators of p21 have been assessed. WT1 is known to induce p21 transcription, and overexpression of WT1 results in altered stem cell cycling and differentiation in primary hematopoietic cells (Ellisen et al., 2001) . Also, it is well documented that p21 is also transcriptionally regulated by p53 and serves as a downstream mediator of cell cycle arrest (El-Deiry et al., 1992; el-Deiry, 1998) . It would be reasonable to expect the HSC phenotype of the p53À/À animal to be similar to that of p21À/À. In fact, in the absence of p53, HSC function has been reported to be significantly enhanced under stress conditions (Wlodarski et al., 1998; Hirabayashi et al., 2002) in a manner opposite to that found in the absence of p21 during long-term engraftment. Since one of the major cellular functions of p53 is to initiate cell death upon genotoxic stress, the enhanced function of HSCs in the absence of p53 suggests that increased survival may predominate over the accelerated proliferation of HSCs in some settings. One alternative explanation is that p21 may affect the stem cells in a p53-independent pathway. This latter possibility is indirectly supported by a recent study where an increase of neuronal regeneration in p21À/À but not p53À/À brain was observed after the ischemic injury (Qiu et al., 2004) .
p27: a progenitor-specific inhibitor to the repopulation efficiency Unlike p21, p27 mRNA is present ubiquitously in all hematopoietic cell populations and p27 protein is primarily regulated by the degradation mechanisms (Carrano et al., 1999) . Direct flow cytometric analysis shows p27 expression in primitive cells (Tong and Srour, 1998) and in more mature progenitors (Taniguchi et al., 1999; Yaroslavskiy et al., 1999) . Using p27À/À mice in conjunction with the hematopoietic reconstitution assay, it has been reported that p27 does not affect HSC number, cell cycling, or self-renewal, but markedly alters HPC proliferation and pool size as assessed by the colony-forming cell (CFC) assay (Cheng et al., 2000a) . When competitively transplanted, p27-deficient HSC generated progenitors that eventually dominated blood cell production. Thus, modulating p27 expression in a small number of stem cells without necessarily expanding the cells may translate into effects on the majority of mature cells, thereby providing a strategy for potentiating the impact of transduced cells in stem cell gene therapies. While this paradigm is yet to be further defined in a regulatable gene targeting system in HSCs, it has been supported indirectly by improved retroviral transduction following knockdown of p27 with an antisense oligonucleotide in human CD34 þ CD38 À cells (Dao et al., 1998) . Therefore, the functional role of p27 on HSC is indirect and appears to be quite distinct from that of p21.
The specific role of p27 in neural progenitors has been also well defined. In adult or developing mouse brain, p27 protein is associated with the NPCs (Legrier et al., 2001) . Expression of p27 in mouse cerebellar granule cell precursor inversely correlates with BrdU incorporation in the cells, and disruption of the p27 gene yields a larger precursor pool (Miyazawa et al., 2000) . p27 was also documented as an intrinsic timer during the proliferation of oligodentricyte cells in vitro (Gao et al., 1997; Burton et al., 1999) . In the absence of p27, those cultured NPCs cells would divide for one more round. In one elegant in vivo study involving the use of more defined NSCs versus NPCs in adult mouse subventricular zone (SVZ), the authors found that loss of p27 had no effect on the number of NSC but selectively increased the number of NPC concomitantly with a reduction in the number of neuroblasts (Doetsch et al., 2002) . The similar advantage of p27-null cells, as demonstrated in hematopoietic reconstitution model during cell engraftment, was reported in liver regeneration mode, suggesting a similar role of p27 in liver progenitors (Karnezis et al., 2001 ). p27 appears to accumulate at points in which signals for mitosis affect cell cycle regulators, and it has been shown to serve as an important regulator at a restriction point for mitogenic signals in many cell types (Coats et al., 1996) . As progenitor cells are highly responsive to growth factors, though in a tissue-specific fashion, p27 must be a critical cell cycle mediator of many cytokines in progenitor cells. p27 was originally cloned in the TGF-b1-treated cell line as a TGF-b1 responsive gene (Polyak et al., 1994) . In the hematopoietic system, TGFb1 has been extensively characterized as a dominantnegative regulator of hematopoietic cell proliferation (Hatzfeld et al., 1991; Cardoso et al., 1993; Fortunel et al., 1998; Cashman et al., 1999) . Antisense TGF-b1 or neutralizing antibodies of TGF-b1 have been used to augment retroviral gene transduction in conjunction with downregulation of p27 in human CD34 þ subsets (Hatzfeld et al., 1991 (Hatzfeld et al., , 1996 Dao et al., 1998) . Therefore, it has been hypothesized that p27 mediates the effect of TGF-b1 in HPCs . In an attempt to further investigate the coordinated regulation of TGF-b1 , p27 was analysed in the cytokine-responsive 32D cell line. Despite the marked antiproliferative effects of TGF-b1, the expression of p27 was not altered. Further, HPCs derived from mice engineered to be deficient in p27 were inhibited by TGFb1 to an equivalent degree of HPCs from the wild-type littermate controls. These data indicated that TGF-b1 exerts its inhibition on cell cycling independent of p27 in HPCs. Therefore, the exact upstream regulators for p27 in a variety of progenitor cells are still somewhat elusive and perhaps depend on the tissue type. Given the presence of mRNA in both stem and progenitor cell populations and the selective inhibition of p27 to progenitors, it is likely that the ubiquitin-proteasome machinery plays a key role in the degradation of p27 protein in these cell types. It would be interesting to look at how differently the F-box Skp2 functions as the substrate-specific subunits of an ubiquitin ligase enzyme for p27 protein in stem cells in response to upstream stem cell regulators (Carrano et al., 1999) .
p18: a strong inhibitor for stem cell self-renewal p18, an INK4 family member, is expressed in multiple tissue types including hematopoietic cells (Tschan et al., 1999) and neurogenic cells (Legrier et al., 2001) . Further, p18 has been suggested to be involved in the symmetric division of precursor cells in developing mouse brain (Tschan et al., 1999) . Recent studies demonstrated an intriguing role of p18 in HSC selfrenewal, whose roles are quite distinct from other CKIs (Cheng et al., 2000a, b; Yuan, et al., 2004) . The absence of p18 causes enhanced stem cell renewal, leading to an increased stem cell pool. In the setting of transplantation, p18-deficient HSCs replicate with stronger competitiveness and permit sequential transplantation strikingly beyond that of wild-type cells. Unlike previous demonstrations in p27-deficient mice, in which the pool size and cell cycling of committed HPCs but not HSCs are markedly increased (Cheng et al., 2000a) , the Cell cycle inhibitors in stem cells T Cheng engraftment advantage in the absence of p18 is not due to predominant outgrowth of less restricted cell cycling in committed HPC pools and more differentiated cell populations or the outgrowth of a single lineage. Further analysis indicates an increase of the highly enriched HSC phenotype but not the lineage-committed progenitor pools. Therefore, the study suggests a relatively specific effect of p18 loss on HSCs and early multipotent HPCs. Interestingly, while both p18 and p21appear to affect kinetics in HSCs, they have very distinct phenotypes: p21À/À HSCs undergo premature exhaustion (Cheng et al., 2000b) but p18À/À HSCs tend to self-renew during long-term engraftment. Without overwhelmingly nonspecific proliferation in other cell populations, increased regeneration of p18À/À HSCs suggests that the balance of differentiation to self-renewal in the absence of p18 favors self-renewal. These two contrasting models also suggest that relative stem cell quiescence or slow cycling is not necessarily the countering force for stem cell self-renewal and, in fact, it might be required for stem cell renewal at least in vivo under homeostatic conditions. While this is a highly speculative point, it would be a reasonable argument, especially given the facts that HSCs can rapidly divide in vitro but they lose self-renewing potential after a few divisions (Ema et al., 2000) . This notion of favored self-renewal in the absence of p18 is indirectly supported by the data from others demonstrating that p18-expressing cells have an increase in asymmetric division Cunningham and Roussel, 2001 ). The mechanism of favored HSC symmetric division may also be associated with the increase of the absolute rate of HSC cycling. This possibility cannot be ruled out based on the current study (Yuan et al., 2004) . But the net HSC expansion would argue against it as a sole mechanism for the increased HSC self-renewal. It is believed that critical decisions of cell fate are made during the G1 phase (Pardee, 1989) . Given the distinct effects of these two CKI members acting on different CDK targets in stem cell regulation (Cheng et al., 2000a, b; Park et al., 2003) , we may propose a model in which modulation of a distinct CKI or its class at a specific position of the cell cycle may be an important mechanism for balancing self-renewal and differentiation in stem cells (Figure 2) .
The regulation for p18 gene and protein in stem cells is unclear at this moment. Given the striking outcome of p18 absence on stem cell renewal, it would be of great appeal to specifically look for the link of p18 with several major signaling pathways controlling stem cell self-renewal. Studies have demonstrated that a subset of osteoblastic cells in the bone marrow serve as niches to regulate the HSC numbers (Calvi et al., 2003; Zhang et al., 2003) and those osteoblastic niches act on the stem cell by activating the Notch1 pathway (Varnum-Finney et al., 2000; Stier et al., 2002) , leading to stem cell expansion. Moreover, another potent stem cell mitogen, the Wnt3a signal acting through the b-catenin pathway, can upregulate the Notch1 pathway and HoxB4, a powerful transcription factor for stem cell self-renewal (Austin et al., 1997; Reya et al., 2003; Willert et al., 2003) . The studies on possible links of upstream regulators of stem cell function and p18, along with other CKIs, will therefore begin to emerge and provide a better understanding of the larger regulatory network in the stem cells.
The p16-Rb pathway in stem cell regulation
One of the best-studied pathways in cell cycle regulation is that of Rb, which directly interacts with Cyclin D and the INK4 proteins in early G-1 phase and serves as a critical and initial interface between mitogenic stimuli and cell fate commitment following cell division. Mice deficient in Rb are not viable and show defects in multiple tissue types including the hematopoietic lineage (Clarke et al., 1992; Jacks et al., 1992; Lee et al., 1992) . Deficient hematopoiesis in RbÀ/À mice indicated that this protein might be critical to stem cell function. However, more definitive studies in the stem cell compartment were largely precluded due to the early lethality of the Rb-null embryo. Instead, INK4 proteins closely associated with Rb have been studied in the context of stem cell biology. These studies include a recent report indicating that Bmi-1, an upstream inhibitor of p16 and p19 ARF (note that it is not the p19 INK4D ) expression, is critical for HSC self-renewal . In the absence of Bmi-1, self-renewal of HSC or NSC is diminished, an effect which is (Cheng et al., 2000b; Cheng et al., 2001 ) and stem cell self-renewal is balanced with differentiation. Model II: under a specific manipulation such as targeting p18 in early G1 phase, stem cell self-renewal can be substantially increased while stem cells remain normal differentiation potential . If a highly controllable or reversible system is developed, this model may have important implications for therapeutic use of stem cells in tissue regeneration. Model III: Additional disruption of cell cycle inhibitors such as p16 or p15 in stem cells coupled with impaired differentiation or apoptosis may contribute to the formation of TSCs, thereby leading tumorigenesis . The size of dark area in G1 phase indicates levels of the cell cycle inhibitors and the irregular shape in Model III indicates irreversible disruption of specific cell cycle inhibitors toward tumorigenesis
Cell cycle inhibitors in stem cells T Cheng dependent on the expression of p16 (Molofsky et al., 2003; Park et al., 2003) . Notably, from the study, p16 only partially mediated the effect of Bmi-1 protein in NSCs, thereby suggesting that other CKIs may participate in the effect of Bmi-1 on stem cell self-renewal. But whether p16 null has the same effect as p18 null does on HSC self-renewal, if vigorously examined by the HSC transplant models, is yet to be defined. More importantly, given the fact that p16 or Rb protein are much more frequently inactivated in cancer cells compared with other CKIs, it would be very interesting to investigate what the physiological roles of these proteins are under homeostasis and how differently these proteins may contribute to the formation of TSC under oncogenic insults (more discussions below).
CKIs and TSCs
Understanding the molecular mechanisms of cell cycle control in stem cells would not only guide us to design rational strategies for stem cell therapies in regenerative medicine but also offer insights into the molecular understanding of stem cell-involved tumorigenesis. As the cell surface markers for TSCs have just begun to be revealed in a few tissue types, data on the roles of CKIs or other cell cycle regulators are not available in the strictly defined TSC populations. Discussions about CKIs in TSCs here are based on analyses of normal stem cells, tumor cell lines, primary tumor samples and phenotypes of mice deficient in the CKIs. Therefore, many points are speculative with indirect evidence.
The concept of TSC
The existence of TSC was proposed several decades ago , but phenotypic characterization of TSC has only gained experimental support in recent years. Following the work on human acute myeloid leukemia (AML) (Bonnet and Dick, 1997) , it has been recently reported that TSC may also exist in human solid tumors such as breast cancer (Al-Hajj et al., 2003) and brain tumors. It is expected that similar findings will be reported in many other cancer types in the coming years (details reviewed by others in this issue). A key element of the TSC concept is to apply the basic rules of stem cell biology in the context of cancer development and therapies. By extension, a tumor is viewed as a heterogeneous and regenerative tissue that is able to outcompete its normal counterpart; TSC is responsible for the initiation and maintenance of an abnormal tissue. This view is reasonable given that traditional chemotherapies or radiotherapies can shrink a tumor but often cannot completely eradiate it. This limitation might be partially attributed to the inability of these conventional therapies to effectively target TSCs embedded in a given tumor mass (Reya et al., 2001) . Studies in leukemia development indicate that TSC may directly derive from either HSCs or HPCs, based on the experiments where a specific oncogenic fusion protein was transduced into phenotypically defined HSCs or HPCs (Passegue et al., 2003) . However, the conclusion regarding direct formation of TSC at the progenitor cell level does not necessarily exclude the possible contribution of stem cells to tumorigenesis at the onset. Tumorigenesis is a process in which multiple genetic or epigenetic changes are accumulated, ultimately resulting in the outgrowth of an abnormal tissue over normal tissues. In theory, tumor development might initiate from stem cells because stem cells are the cell type that can self-renew for a lifetime in the body with the most chances of being exposed to many chronic oncogenic insults. In contrast, the majority of progenitor cells are short-lived with a high turnover rate. If a 'normal' stem cell does not directly transform into a TSC, then it may pass on a certain degree of tumorigenesis susceptibility into the progenitor cells depending on the history of oncogenic insults that the stem cell has encountered. Given these assumptions, we may largely utilize the current knowledge of molecular genetics or epigenetics in tumor biology. For example, it has been extensively studied that disruption of the two major tumor-suppressor pathways, namely the p16-Rb and ARF-p53 pathways, largely participates in the development of most cancer types (Sherr, 2001) . It would be interesting to know how these critical events may be manifested by TSCs upon causative oncogenic insults. However, given that the TSCs are a very small cell population in a heterogeneous tumor tissue, like normal stem cells, rarity of TSCs would certainly pose a technical challenge to our research especially in solid tumors.
Relevance of CKIs to general tumor occurrence
In human cancers, Cip/Kip members (p21, p27 and p57) are rarely found to be mutated or silenced, but may be important mediators or targets of tumor suppressors or oncoproteins. For example, p21 is transcriptionally regulated by p53 in cell cycle arrest. p27 has been shown to be a target of several oncogenes such as E1A (Mal et al., 1996) and c-Myc (Steiner et al., 1995) . The lower expression of p27 protein has been reported to be associated with the prognostic of many human cancer types (Bloom and Pagano, 2003) . In contrast, the INK4 family member, p16 and its related protein p14 ARF have been defined as tumor-suppressor genes, and are frequently inactivated in human cancers. For example, based on a survey on 4700 primary cases of leukemia or lymphoma and some 320 continuous leukemia-lymphoma cell lines, p16 and p15 are frequently deleted or silenced by the hypermethylation in their promoters; in contrast, very few cases had p18 or p19 deletion or hypermethylation (Drexler, 1998) .
Interestingly, these genetic or epigenetic data in human cancers seem to be at least partially in agreement with the occurrence of tumor development in the mice deficient in CKIs. All the knockout animals except p57-null mice (Zhang et al., 1997) exhibit normal organ development, but sharply differ in tumor susceptibility. Therefore, CKIs can be divided into three categories based on the frequency of tumor formation in those knockout mice. (1) Tumor suppressors (p16 and p15): Mice lacking p16 have thymic hyperplasia with enhanced mitogenic responsiveness in T cells. Like p19 ARF deficiency, p16 deficiency is associated with an increased incidence of spontaneous and carcinogen-induced cancers (Sharpless et al., 2001) . To a less degree, loss of p15 confers proliferative advantage to the cultured cells and sensitizes these cells to H-ras induced transformation and results in a low incidence of angiosarcomas in the mice (Latres et al., 2000) . In addition, p15 deficiency also enhances susceptibility to retrovirus-induced AML in mice. (2) Haplo-insufficient tumor suppressors (p27 and p18): Disruption of both alleles of p27 or p18 gene in mice results in organomegaly with higher cellularity and an increase in the incidence of spontaneous pituitary tumor with advanced age or multiple tumor types in the presence of carcinogens (Fero et al., 1996; Nakayama et al., 1996; Franklin et al., 1998 Franklin et al., , 2000 Bai et al., 2003) . In addition, p27 or p18 is able to sensitize mice to gamma-irradiation-or chemical carcinogeninduced tumorigenesis (Fero et al., 1998; Bai et al., 2003) . (3) Nontumor suppressors (p21 and p19): Unlike other CKIs, p21-null or p19-null mice have a normal life span and do not spontaneously develop tumors (Brugarolas et al., 1995; Deng et al., 1995; Zindy et al., 2000) . Among the above different groups, there are also specific collaborative effects between some of the CKIs or their related proteins, such as p16 and p19 ARF (Sharpless et al., 2004) or p27 and p18 or p15 and p18 (Latres et al., 2000) , indicating the crosstalk of different pathways. Together, these results indicate the differential roles of CKIs in cancer development. p16 and p15 are the most relevant CKIs to cancers based on the current data in both humans and mice. Give the broad expression of CKIs and similar substrates of each CKI subfamily in cell cycle, it is puzzling why these molecules exhibit strikingly different tumor susceptibilities with limited compensatory effects.
Potential roles of CKIs in TSC and therapeutic implications
The differences of tumor susceptibility in the CKI knockout animals suggest that these proteins may act in different differentiation stages and pathways, thereby intersecting differently with other key pathways involved in tumorigenesis. The distinct roles of different CKIs in stem/progenitor cells offer unique insights into to the roles of CKIs in tumorigenesis. If there is a TSC, then the TSC needs to have an increased cell survival or a higher self-renewing potential rate than that of the normal stem cells in a given tissue in order to develop a dominant tumor mass. Thus, understanding the cell cycle basis underlying self-renewal of TSCs versus normal stem cells is a key subject in the field. Recent studies showed that TSCs and normal stem cells share the mechanisms for self-renewal, such as the Bmi-1 and b-catenin pathways (Lessard and Sauvageau, 2003; Reya et al., 2003; Park et al., 2004) . p16 and p19 In an attempt to further demonstrate the different involvements of CKIs in TSC formation, reconstitution experiments with p18-null hematopoietic cells have been followed up for more than 2 years (Yuan, et al., 2003) . Enhanced self-renewal of p18null-HSC has been sustained without evidence of leukemogenesis at the stem cell level. At the later stage, a small percentage of the transplanted mice developed acute T-cell leukemia, but the development of the leukemia involved the methylation of p15 or p16 promoter in addition to the absence of p18. Interestingly, HSCs isolated from these leukemic mice did not readily transfer the leukemic phenotype in the secondary recipients. These results support a notion that increased stem cell self-renewal by the downregulation of p18 is not sufficient to cause leukemia and the disruption of p16 or p15 may set the stage of forming the leukemia stem cells to outcompete the normal hematopoiesis (Figure 2 ). These data, together with our studies about the physiological roles of p21 and p27 described above, pose an intriguing possibility that normal and TSCs favor different downstream mediators such as different CKIs. Targeting some less tumor-prone CKI genes might be a worthwhile approach for stem cell expansion as indicated in previous studies (Antonchuk et al., 2002; Krosl et al., 2003; Stier et al., 2003) . We must, however, bear in mind that 'benign gene' in tumorigenesis is a relative term and many genes can contribute to cancer development depending on the actual context. The long-term effect of modifying these genes or gene products should be carefully examined and must be in a regulatable manner in order to develop a clinically acceptable protocol.
Future studies on TSC will focus on the following questions. How do different CKIs respond to the upstream signaling pathways such as Hox proteins, Wnt-b-catenin, Notch-1, and Bmi-1? Is there a common cell cycle switch in different stem cell populations? How different is the switch in normal and TSCs? For those relatively 'benign' CKIs such as p21 or p18, to what extent can we target or express the molecule for normal stem cell expansion without the occurrence of tumorigenesis?
Closing remarks
The critical roles of cell cycle inhibitors, particularly different CKIs, represent an interface of complex extracellular signals and their transduction in stem cell regulation. Different members of the CKI subfamilies play distinct roles in stem or progenitor cell populations. The function of the different CKIs appears to be highly differentiation-stage-specific and confers an important level of regulation in stem or progenitor cells to maintain homeostasis. The mouse models deficient in p21, p27 or p18 have offered unique tools for studying stem cell quiescence, repopulation capacity or selfrenewal. Cooperative effects between members of the two CKI subfamilies are likely, given the evidence of interplay between RB and p53 pathways. How the CKIs exert distinct effects and the pathways converging on these regulators are the subjects of ongoing studies and will potentially provide further insights for manipulation of stem and progenitor cells. While the distinct roles for these CKIs have been largely defined in hematopoietic cells, several lines of evidence suggest that these distinctions may be preserved across stem and progenitor pools from different adult tissues, thereby offering a platform for future therapeutic efforts based on the molecular commonality of cell cycle control. It should be noted that mouse ES stem cells have not shown the same cell cycle characteristics as adult stem cell populations (Aladjem et al., 1998; Burdon et al., 2002) and so the content discussed in this article would not apply to ES cells. In addition, the ultimate success of therapeutic manipulations for stem cells in regenerative medicine will also require a greater understanding of the interaction between stem cell and microenvironment ('niche') through the signaling circuitry and cell cycle progression involved in achieving self-renewal (Calvi et al., 2003) .
Uncovering the mechanisms for cell cycle control underlying stem cell self-renewal will eventually lead to greater insights into stem cell biology, thereby providing new strategies for normal tissue regeneration, tumorigenesis and possibly tumor therapies. However, the cell cycle control is only one of the important aspects in TSC biology. The self-renewing divisions of stem cells must be balanced physiologically with cell death or differentiation. If a tumor originates from the transformation of a normal cell, then the TSC must require a competitive self-renewal potential coupled with decreased cell death or a disrupted differentiation program in order to outcompete the normal counterpart. In addition, there must be an appropriate local microenvironment (possibly altered stromal cell elements or 'niches' for TSCs) and newly developed vascularization to cultivate the tumor growth. Finally, TSCs must also acquire an ability to elude the body's immune system. Nevertheless, deregulated cell cycle control must be one of the fundamentally intrinsic steps leading to TSCderived tumorigenesis (Figure 2) . A greater understanding of the coordination of cell cycle regulation with cell differentiation and survival in stem cells under physiological cues or oncogenic insults is a central question in TSC biology as well as tissue regeneration. The answer to this question will maximize our ability to expand stem cells for normal tissue regeneration, and meanwhile prevent the normal stem cells from becoming cancerous or selectively eradicate malignant stem cells. Does this sound too good to be true? Once we know the molecular boundary between normal and TSCs and have the ability to manipulate the key circuitry, it will become a reality!
